padsevonil

an antiepileptic drug

Also Known As:

(4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)-2-pyrrolidinone; 2-Pyrrolidinone, 4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)-1,3,4-thiadiazol-5-yl)methyl)-, (4R)-

Networked: 7 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kaminski, Rafal M: 2 articles (01/2020 - 01/2020)
2.	Löscher, Wolfgang: 1 article (01/2021)
3.	Brandt, Christian: 1 article (01/2020)
4.	DeBruyn, Steven: 1 article (01/2020)
5.	Germani, Massimiliano: 1 article (01/2020)
6.	Hannestad, Jonas: 1 article (01/2020)
7.	Klitgaard, Henrik: 1 article (01/2020)
8.	Lacroix, Brigitte: 1 article (01/2020)
9.	Leclercq, Karine: 1 article (01/2020)
10.	Majoie, Marian: 1 article (01/2020)

Related Diseases

1.	Seizures (Absence Seizure) 01/01/2020 - "In the amygdala kindling model, which is predictive of efficacy against focal to bilateral tonic-clonic seizures, padsevonil provided significant protection in kindled rodents; in mice specifically, it was the most potent AED compared with nine others with different mechanisms of action. " 12/01/2022 - "To characterize efficacy, safety/tolerability, and pharmacokinetics of padsevonil (PSL) administered concomitantly with ≤3 antiseizure medications (ASMs) for observable focal seizures in adults with drug-resistant epilepsy in two multicenter, randomized, double-blind, placebo-controlled, parallel-group trials. " 01/01/2020 - "Adults with highly treatment-resistant epilepsy, who were experiencing ≥4 focal seizures/week, and had failed to respond to ≥4 antiepileptic drugs, were randomized to receive placebo or padsevonil as add-on to their stable regimen. " 01/01/2020 - "In acute seizure models, padsevonil provided potent, dose-dependent protection against seizures induced by administration of pilocarpine or 11-deoxycortisol, and those induced acoustically or through 6 Hz stimulation; it was less potent in the pentylenetetrazol, bicuculline, and maximal electroshock models. "
2.	Epilepsy (Aura) 01/01/2020 - "Padsevonil was associated with a favourable safety profile and displayed clinically meaningful efficacy in patients with treatment-resistant epilepsy. " 01/01/2021 - "Although this strategy has been proposed for epilepsy therapy >25 years ago, to my knowledge, only one antiseizure medication (ASM), padsevonil, has been intentionally developed as a single molecular entity that could target two different mechanisms. " 01/01/2020 - "Overall, padsevonil displayed robust efficacy across validated seizure and epilepsy models, including those considered to represent drug-resistant epilepsy. " 01/01/2020 - "Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models." 01/01/2020 - "Padsevonil displayed dose-dependent protective effects in chronic epilepsy models, including the intrahippocampal kainate and Genetic Absence Epilepsy Rats from Strasbourg models, which represent human mesial temporal lobe and absence epilepsy, respectively. "
3.	Absence Epilepsy (Childhood Absence Epilepsy) 01/01/2020 - "Padsevonil displayed dose-dependent protective effects in chronic epilepsy models, including the intrahippocampal kainate and Genetic Absence Epilepsy Rats from Strasbourg models, which represent human mesial temporal lobe and absence epilepsy, respectively. "
4.	Partial Epilepsies (Epilepsy, Partial) 12/01/2022 - "Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: Results from two double-blind, randomized, placebo-controlled trials." 01/01/2021 - "However, in a recent randomized placebo-controlled phase IIb add-on trial in treatment-resistant focal epilepsy patients, padsevonil did not separate from placebo in its primary endpoints. " 01/01/2020 - "Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach." 01/01/2018 - "Among AEDs in Phase II development, Cannabidavirin, Padsevonil and Selurampanel may represent a promising fourth generation of compounds for focal epilepsies if they successfully proceed to subsequent stages. " 12/01/2022 - "For adult focal epilepsies, padsevonil and carisbamate are at a more advanced Phase III stage of clinical development followed by compounds at Phase II like selurampanel, XEN1101 and JNJ-40411813. "
5.	Drug Resistant Epilepsy 12/01/2022 - "To characterize efficacy, safety/tolerability, and pharmacokinetics of padsevonil (PSL) administered concomitantly with ≤3 antiseizure medications (ASMs) for observable focal seizures in adults with drug-resistant epilepsy in two multicenter, randomized, double-blind, placebo-controlled, parallel-group trials. " 01/01/2020 - "Overall, padsevonil displayed robust efficacy across validated seizure and epilepsy models, including those considered to represent drug-resistant epilepsy. "

Related Drugs and Biologics

1.	Pilocarpine (Ocusert)
2.	Pentylenetetrazole (Metrazol)
3.	Kainic Acid (Kainate)
4.	Cortodoxone (11 Deoxycortisol)
5.	Bicuculline
6.	Anticonvulsants (Antiepileptic Drugs)
7.	selurampanel
8.	Minocycline (Cyclops)
9.	Ligands
10.	Levetiracetam (Keppra)

Related Therapies and Procedures

1.	Therapeutics